Harfst & Associates’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,732
| Closed | -$836K | – | 121 |
|
|
2025
Q1 | $836K | Sell |
3,732
-3,908
| -51% | -$1.08M | 0.19% | 62 |
|
|
2024
Q4 | $2.5M | Buy |
7,640
+156
| +2% | +$49.1K | 0.52% | 37 |
|
|
2024
Q3 | $2.25M | Buy |
7,484
+551
| +8% | +$169K | 0.5% | 40 |
|
|
2024
Q2 | $2.28M | Buy |
6,933
+106
| +2% | +$37.5K | 0.53% | 34 |
|
|
2024
Q1 | $2.7M | Sell |
6,827
-153
| -2% | -$56.6K | 0.64% | 24 |
|
|
2023
Q4 | $2.46M | Sell |
6,980
-165
| -2% | -$58.4K | 0.65% | 28 |
|
|
2023
Q3 | $2.68M | Sell |
7,145
-12
| -0.2% | -$4.64K | 0.75% | 19 |
|
|
2023
Q2 | $2.74M | Buy |
7,157
+65
| +0.9% | +$23.2K | 0.73% | 20 |
|
|
2023
Q1 | $2.46M | Sell |
7,092
-7
| -0.1% | -$2.04K | 0.7% | 20 |
|
|
2022
Q4 | $1.67M | Buy |
7,099
+260
| +4% | +$61.6K | 0.48% | 41 |
|
|
2022
Q3 | $1.68M | Buy |
6,839
+577
| +9% | +$176K | 0.51% | 37 |
|
|
2022
Q2 | $1.89M | Sell |
6,262
-255
| -4% | -$83K | 0.54% | 25 |
|
|
2022
Q1 | $2.68M | Buy |
6,517
+539
| +9% | +$211K | 0.62% | 18 |
|
|
2021
Q4 | $2.8M | Buy |
5,978
+302
| +5% | +$130K | 0.71% | 14 |
|
|
2021
Q3 | $2.41M | Sell |
5,676
-299
| -5% | -$126K | 0.67% | 16 |
|
|
2021
Q2 | $2.15M | Sell |
5,975
-361
| -6% | -$119K | 0.62% | 20 |
|
|
2021
Q1 | $1.78M | Buy |
6,336
+1,095
| +21% | +$313K | 0.54% | 31 |
|
|
2020
Q4 | $1.48M | Buy |
5,241
+376
| +8% | +$106K | 0.55% | 23 |
|
|
2020
Q3 | $1.34M | Sell |
4,865
-1,128
| -19% | -$299K | 0.57% | 19 |
|
|
2020
Q2 | $1.36M | Sell |
5,993
-346
| -5% | -$68K | 0.59% | 16 |
|
|
2020
Q1 | $965K | Buy |
6,339
+211
| +3% | +$32.5K | 0.49% | 23 |
|
|
2019
Q4 | $921K | Buy |
6,128
+93
| +2% | +$13.5K | 0.35% | 37 |
|
|
2019
Q3 | $855K | Buy |
6,035
+48
| +0.8% | +$6.61K | 0.35% | 32 |
|
|
2019
Q2 | $749K | Buy |
5,987
+341
| +6% | +$40.3K | 0.31% | 37 |
|
|
2019
Q1 | $622K | Buy |
5,646
+882
| +19% | +$91.7K | 0.27% | 44 |
|
|
2018
Q4 | $467K | Buy |
4,764
+403
| +9% | +$43.7K | 0.22% | 51 |
|
|
2018
Q3 | $538K | Buy |
4,361
+154
| +4% | +$17.3K | 0.23% | 40 |
|
|
2018
Q2 | $417K | Buy |
4,207
+75
| +2% | +$6.9K | 0.18% | 49 |
|
|
2018
Q1 | $364K | Buy |
4,132
+193
| +5% | +$18.1K | 0.15% | 62 |
|
|
2017
Q4 | $388K | Buy |
3,939
+132
| +3% | +$12.9K | 0.16% | 57 |
|
|
2017
Q3 | $366K | Hold |
3,807
| – | – | 0.15% | 54 |
|
|
2017
Q2 | $359K | Buy |
3,807
+1,519
| +66% | +$140K | 0.14% | 51 |
|
|
2017
Q1 | $186K | Buy |
+2,288
| New | +$191K | 0.08% | 80 |
|
Other funds holding WST
Harfst & Associates's WST Position: Q2 2025 in Review
Harfst & Associates sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 3,732 shares — an estimated $836K sold.
Harfst & Associates first reported a position in WST in Q1 2017 and held it in 33 quarters. The position peaked at $2.8M in Q4 2021. 731 funds tracked by Wall St. Rank hold WST as of Q2 2025.
- Harfst & Associates reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
- Harfst & Associates sold 3,732 West Pharmaceutical shares in Q2 2025, an estimated $836K.
- Harfst & Associates first reported a position in West Pharmaceutical in Q1 2017 and held it in 33 quarters.
- Harfst & Associates's West Pharmaceutical position peaked at $2.8M in Q4 2021.
- 731 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.
Based on Harfst & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.